DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

1.46 0.06 (4.29%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PLX $1.46 4.29%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.43
Previous Close $1.40
Daily Range $1.40 - $1.48
52-Week Range $1.33 - $3.00
Market Cap $137.5M
P/E Ratio -4.83
Dividend (Yield) $0.00 (0.0%)
Volume 24,716
Average Daily Volume 117,147
Current FY EPS -$0.31

Sector

Healthcare

Industry

Drug Makers

Protalix BioTherapeutics, Inc. (PLX) Description

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system. Website: http://www.protalix.com/

News & Commentary

3 High-Risk, High-Reward Biotech Stocks for Long Term Investors

Everyone wants to get rich, but investing in the wrong developmental companies can have disastrous consequences. Here are three companies with game-changing potential that have yet to hit their stride -- and may payoff in the long run.

Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Pr

Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity

Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis

Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference

Can Protalix BioTherapeutics Deliver?

Surging Earnings Estimates Signal Good News for Protalix BioTherapeutics (PLX) - Tale of the Tape

Protalix BioTherapeutics (PLX) Shares March Higher, Can It Continue? - Tale of the Tape

Protalix BioTherapeutics (PLX) Shares March Higher, Can It Continue? - Tale of the Tape

Why Protalix BioTherapeutics (PLX) Stock Might be a Great Pick - Tale of the Tape

Protalix BioTherapeutics (PLX): An Off-the-Radar Potential Winner - Tale of the Tape

Protalix BioTherapeutics (PLX): An Off-the-Radar Potential Winner - Tale of the Tape

Health Care Sector Update for 02/12/2015: PLX, THLD, ACOR

Protalix Finishes Patient Enrollment for Fabry Disease Study - Analyst Blog

Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

See More PLX News...

PLX's Top Competitors

PLX $1.46 (4.29%)
Current stock: PLX
AMGN $155.89 (0.11%)
Current stock: AMGN
GILD $107.78 (-0.19%)
Current stock: GILD
BIIB $303.69 (-0.26%)
Current stock: BIIB